Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter's Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1. Drivers
4.1.1 Growth in the Number of Diabetic Patients
4.1.2 Increasing Population Exposure to Key Risk Factors Leading to Diabetes
4.1.3 Rising Market Demand for HI Analogs
4.1.4 Technological Advancements in HI Delivery Devices
4.1.5 Favourable Medical Reimbursement Scenario in Developed Countries
4.2 Restraints
4.2.1 Stringent Regulatory Requirements for Product Approval
4.3 Opportunities
4.3.1 Expected Patent Expiry of Key HI Drugs
4.3.2 Emerging Markets
4.4 Challenges
4.4.1 High Product Manufacturing Costs
Chapter 5 Asia-Pacific Insulin Market– By Product Type
5.1 Drugs
5.2 Delivery Devices
Chapter 6 Asia-Pacific Insulin Market– By Type
6.1 Insulin Analogs
6.2 Biosimilars
6.3 Biologics
Chapter 7 Asia-Pacific Insulin Market- By Delivery Devices
7.1 Syringes
7.2 Pens
7.3 Pen Needles
Chapter 8 Asia-Pacific Insulin Market- By Application
8.1 Type I Diabetes
8.2 Type II Diabetes
Chapter 9 Asia-Pacific Insulin Market- By Geography
9.1 Introduction
9.2 China
9.3 Japan
9.4 India
9.5 South Korea
9.5 Australia & New Zealand
9.6 Rest of APAC
Chapter 10 Asia-Pacific Insulin Market- Company Profiles
10.1B. Braun Melsungen AG
10.1.1. Company Overview
10.1.2. Business Segments
10.1.3. Financial Performance ( Public Enterprises)
10.1.4. SWOT Analysis
10.2 Biocon Limited
10.3 Becton, Dickinson and Company
10.4 Eli Lilly and Company
10.5 Biodel Inc.
10.6 Julphar
10.7 NOVO Nordisk A/S
10.8Sanofi
10.9Wockhardt Limited
10.10Ypsomed AG
10.11Oramed Pharmaceuticals Inc.
10.12Dongbao Enterprises Group Co. Ltd.
10.13Merck & Co.
10.14 GlaxoSmithKline Plc
Chapter 10 Asia-Pacific Insulin Market- Competitive Landscape
10.1. Market Share Analysis
10.2. Strategies Adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
Chapter 11 Market Insights
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
Chapter 12 Appendix
12.1 List of Tables
12.2 List of Figures
